The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Kidney Fibrosis Treatment Market Change Between 2026 And 2030?
The kidney fibrosis treatment market has demonstrated significant growth in recent years. It is anticipated to increase from $6.06 billion in 2025 to $6.54 billion in 2026, with a compound annual growth rate (CAGR) of 8.0%. The expansion observed in previous periods is attributable to factors such as the increasing incidence of chronic kidney disease, the restricted efficacy of traditional therapies, the greater utilization of ACE inhibitors and ARBs, the rising healthcare burden due to renal failure, and the extended provision of nephrology care services.
The kidney fibrosis treatment market size is expected to demonstrate robust growth in the coming years, with projections indicating an expansion to **$8.84 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%**. This growth over the forecast period is primarily driven by advancements in targeted antifibrotic agents, an expanding aging population suffering from chronic kidney disease (CKD), the increasing adoption of precision medicine within nephrology, escalating investments in renal research, and improvements in the early diagnosis of kidney disease. Significant trends anticipated during this period include an intensified focus on the development of antifibrotic drugs, a greater utilization of combination therapies for CKD, a surge in research concerning stem cell and regenerative therapies, the expansion of early diagnostic and monitoring tools, and an increase in clinical trials targeting renal fibrosis pathways.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp
Which Strategic Drivers Are Supporting The Kidney Fibrosis Treatment Market Development?
The expanding occurrence of chronic kidney diseases is set to drive the growth of the kidney fibrosis treatment market. Chronic kidney disease (CKD) is characterized by a progressive decline in kidney function over time, often triggered by conditions such as diabetes or hypertension, which results in the buildup of waste products in the body. The increasing incidence of CKD is largely attributed to the rising prevalence of diabetes, a condition that damages kidney blood vessels and impedes their filtering capacity. Kidney fibrosis treatment offers assistance to CKD patients by addressing the scarring of kidney tissue, reducing inflammation, and decelerating the progression of kidney damage, thereby preserving kidney function. As an illustration, in July 2025, Hamadan University of Medical Sciences, an Iran-based university, projected that the global count of newly diagnosed chronic kidney diseases will escalate to 25.06 million by 2030. Hence, the rising prevalence of chronic kidney diseases is fueling the growth of the kidney fibrosis treatment market.
What Segment Types Are Included In The Kidney Fibrosis Treatment Market Analysis?
The kidney fibrosis treatment market covered in this report is segmented –
1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types
2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests
3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications
4) By End-User: Clinics, Research Center, Hospitals
Subsegments:
1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril
2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan
3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone
4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors
5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat
6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy
Which Trends Are Influencing The Expansion Of The Kidney Fibrosis Treatment Market?
Major companies engaged in the kidney fibrosis treatment market are prioritizing specific ileal-release immunomodulatory therapies, such as NEFECON, which is an oral delayed-release budesonide capsule engineered to deliver the medication directly to the distal ileum. This mechanism modulates gut-associated B-cells and diminishes pathogenic IgA production, thereby decelerating the progression of kidney fibrosis in patients with IgA nephropathy. For instance, in June 2024, Everest Medicines, a China-based biopharmaceutical company, launched NEFECON. This treatment incorporates an enteric-coated, delayed-release formulation to lessen systemic steroid exposure, targets mucosal B-cells in the gut to address the core cause of IgA nephropathy, and has demonstrated a significant capability to reduce the decline in kidney function.
Which Companies Are Engaged In The Kidney Fibrosis Treatment Market Environment?
Major companies operating in the kidney fibrosis treatment market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Chinook Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Reata Pharmaceuticals Inc., ProKidney LLC, Tvardi Therapeutics Inc., Alentis Therapeutics AG, Galecto Biotech AB, Vertex Pharmaceuticals Incorporated, Insilico Medicine Inc., Purespring Therapeutics Inc., La Jolla Pharmaceutical Company, Cara Therapeutics Inc
Access The Complete Kidney Fibrosis Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report
Which Region Holds The Largest Share In The Kidney Fibrosis Treatment Market?
North America was the largest region in the kidney fibrosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Kidney Fibrosis Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp
Browse Through More Reports Similar to the Global Kidney Fibrosis Treatment Market 2026, By The Business Research Company
Chronic Kidney Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report
Late Stage Chronic Kidney Disease Drugs Market Report 2026
Kidney Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model